Finanzen von Tharimmune Inc (THAR)THARTharimmune Inc

Evaluating the bottom line, Tharimmune Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -225.01%, provide a clear picture of how effectively THAR converts its operational activities into shareholder value.

In the context of the broader market, THAR competes directly with industry leaders such as GALT and IMDX. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, THAR's gross margin of N/A stands against GALT's N/A and IMDX's 65.69%. Such benchmarking helps identify whether Tharimmune Inc is trading at a premium or discount relative to its financial performance.

In Q3 2025, revenue remained at 0 with no growth. Net income dropped significantly to -2,101,838 (-44.63% YoY), and EPS fell to -0.34 (-86.12% YoY). Gross margin also remained at 0 with no growth.